Division of Allergy and Immunology, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Blvd., Tampa, FL 33612, USA.
Biochem Biophys Res Commun. 2013 Sep 27;439(3):407-12. doi: 10.1016/j.bbrc.2013.08.056. Epub 2013 Aug 27.
Inflammasomes are multimeric protein complexes involved in the processing of IL-1β through Caspase-1 cleavage. NLRP3 is the most widely studied inflammasome, which has been shown to respond to a large number of both endogenous and exogenous stimuli. Although studies have begun to define basic pathways for the activation of inflammasome and have been instrumental in identifying therapeutics for inflammasome related disorders; understanding the inflammasome activation at the molecular level is still incomplete. Recent functional studies indicate that microRNAs (miRs) regulate molecular pathways and can lead to diseased states when hampered or overexpressed. Mechanisms involving the miRNA regulatory network in the activation of inflammasome and IL-1β processing is yet unknown. This report investigates the involvement of miR-133a-1 in the activation of inflammasome (NLRP3) and IL-1β production. miR-133a-1 is known to target the mitochondrial uncoupling protein 2 (UCP2). The role of UCP2 in inflammasome activation has remained elusive. To understand the role of miR-133a-1 in regulating inflammasome activation, we either overexpressed or suppressed miR-133a-1 in differentiated THP1 cells that express the NLRP3 inflammasome. Levels of Caspase-1 and IL-1β were analyzed by Western blot analysis. For the first time, we showed that overexpression of miR-133a-1 increases Caspase-1 p10 and IL-1β p17 cleavage, concurrently suppressing mitochondrial uncoupling protein 2 (UCP2). Surprisingly, our results demonstrated that miR-133A-1 controls inflammasome activation without affecting the basal expression of the individual inflammasome components NLRP3 and ASC or its immediate downstream targets proIL-1β and pro-Caspase-1. To confirm the involvement of UCP2 in the regulation of inflammasome activation, Caspase-1 p10 and IL-1β p17 cleavage in UCP2 of overexpressed and silenced THP1 cells were studied. Suppression of UCP2 by siRNA enhanced the inflammasome activity stimulated by H2O2 and, conversely, overexpression of UCP2 decreased the inflammasome activation. Collectively, these studies suggest that miR-133a-1 suppresses inflammasome activation via the suppression of UCP2.
炎性小体是一种多聚体蛋白复合物,通过半胱氨酸蛋白酶-1 的切割参与白细胞介素-1β(IL-1β)的加工。NLRP3 是研究最为广泛的炎性小体,其已被证明能够对大量内源性和外源性刺激物作出反应。尽管研究已经开始定义炎性小体激活的基本途径,并有助于鉴定与炎性小体相关疾病的治疗方法;但对分子水平上的炎性小体激活的理解仍然不完整。最近的功能研究表明,微 RNA(miRs)调节分子途径,当受到阻碍或过度表达时,可能导致疾病状态。miRNA 调节网络在炎性小体激活和白细胞介素-1β加工中的作用尚不清楚。本报告研究了 miR-133a-1 在炎性小体(NLRP3)激活和白细胞介素-1β产生中的作用。已知 miR-133a-1 靶向线粒体解偶联蛋白 2(UCP2)。UCP2 在炎性小体激活中的作用仍然难以捉摸。为了了解 miR-133a-1 在调节炎性小体激活中的作用,我们在表达 NLRP3 炎性小体的分化 THP1 细胞中过表达或抑制 miR-133a-1。通过 Western blot 分析分析 Caspase-1 和白细胞介素-1β的水平。我们首次表明,miR-133a-1 的过表达增加了 Caspase-1 p10 和白细胞介素-1β p17 的切割,同时抑制了线粒体解偶联蛋白 2(UCP2)。令人惊讶的是,我们的结果表明,miR-133A-1 控制炎性小体激活,而不影响单个炎性小体成分 NLRP3 和 ASC 的基础表达或其直接下游靶标前白细胞介素-1β和前半胱天冬酶-1。为了确认 UCP2 在调节炎性小体激活中的作用,我们研究了 UCP2 过表达和沉默 THP1 细胞中 Caspase-1 p10 和白细胞介素-1β p17 切割。siRNA 抑制 UCP2 增强了由 H2O2 刺激的炎性小体活性,相反,UCP2 的过表达降低了炎性小体的激活。总的来说,这些研究表明,miR-133a-1 通过抑制 UCP2 来抑制炎性小体的激活。